이 누리집은 대한민국 공식 전자정부 누리집입니다.
Biz News Korea(Eng)
SK Biotek opens pharmaceutical manufacturing facility in Ireland
- Collected
- 2018.01.26
- Distributed
- 2018.01.29
- Source
- Go Direct
![The inauguration ceremony of SK Biotek’s Swords facility held on Thursday (local time) in Ireland was attended by (from left) Korean ambassador to Ireland Hu Kang-il, Eileen Sharpe, Divisional Manager Growth Markets, Europe, Emerging Business, New Forms of Investment at IDA Ireland, Junku Park, chief executive officer of SK Biotek, Michael D`Arcy, Minister of State at the Department of Finance and the Department of Public Expenditure and Reform, James Reilly, a Senator in Ireland. [Photo by SK Group]](http://file.mk.co.kr/meet/neds/2018/01/image_readtop_2018_60618_15169439903185797.jpg)
The inauguration ceremony of SK Biotek’s Swords facility held on Thursday (local time) in Ireland was attended by (from left) Korean ambassador to Ireland Hu Kang-il, Eileen Sharpe, Divisional Manager Growth Markets, Europe, Emerging Business, New Forms of Investment at IDA Ireland, Junku Park, chief executive officer of SK Biotek, Michael D`Arcy, Minister of State at the Department of Finance and the Department of Public Expenditure and Reform, James Reilly, a Senator in Ireland. [Photo by SK Group]
SK Biotek, a rapidly growing CDMO in Korea and wholly-owned subsidiary of SK Holdings, held a ceremony to inaugurate the operation.
In tune with the commencement, 360 BMS staff are shifted SK Biotek and all products are rolled out under the brand name of SK Biotek.
The Swords facility has an 81,000-liter capacity and currently manufactures active pharmaceutical ingredients (APIs) for a number of medicines for patients with cancer, cardiovascular disease and viral disorders.
The company said that it expects the Swords plant to add significantly to revenues as most of key products are supplied to global pharmaceutical companies.
SK Biotek will foster the plant as a springboard to enter the European market beyond its current role as a stand-alone Contract Development Manufacturing Organization (CDMO).
SK Biotek is the first Korean company to invest in pharmaceutical manufacturing in Ireland and anticipates further investment by adding additional manufacturing capabilities, said a company official.
SK Biotek is on track to become a top 10 player in the global CDMO market as it established a marketing organization in the U.S. early this year and unveiled a plan to expand its 320,000 liter capacity to 800,000 liters in total by 2020.
By Kim Hye-soon and Minu Kim
[ⓒ Pulse by Maeil Business News Korea & mk.co.kr, All rights reserved]